Published in Adv Hematol on July 28, 2009
Biomarkers for determining the prognosis in chronic myelogenous leukemia. J Hematol Oncol (2013) 1.05
Diversity of breakpoints of variant Philadelphia chromosomes in chronic myeloid leukemia in Brazilian patients. Rev Bras Hematol Hemoter (2014) 0.82
The Impact of Variant Philadelphia Chromosome Translocations on the Clinical Course of Chronic Myeloid Leukemia. Turk J Haematol (2016) 0.75
Chronic myeloid leukemia. N Engl J Med (1999) 7.11
The biology of chronic myeloid leukemia. N Engl J Med (1999) 4.80
Cytogenetic and molecular genetic evolution of chronic myeloid leukemia. Acta Haematol (2002) 3.34
Large deletions at the t(9;22) breakpoint are common and may identify a poor-prognosis subgroup of patients with chronic myeloid leukemia. Blood (2000) 1.58
Complex translocations, simple variant translocations and Ph-negative cases in chronic myelogenous leukaemia. Hum Genet (1990) 1.32
Imatinib mesylate therapy may overcome the poor prognostic significance of deletions of derivative chromosome 9 in patients with chronic myelogenous leukemia. Blood (2004) 1.28
Minimal residual disease after allogeneic bone marrow transplantation for chronic myeloid leukaemia in first chronic phase: correlations with acute graft-versus-host disease and relapse. Br J Haematol (1993) 1.18
Results of imatinib mesylate therapy in chronic myelogenous leukaemia with variant Philadelphia chromosome. Br J Haematol (2004) 1.14
Chronic myeloid leukemia in chronic phase responding to imatinib: the occurrence of additional cytogenetic abnormalities predicts disease progression. Haematologica (2003) 0.99
Rapid quantitative detection of BCR-ABL transcripts in chronic myeloid leukemia patients by real-time reverse transcriptase polymerase-chain reaction using fluorescently labeled probes. Haematologica (2000) 0.93
ABL-BCR expression does not correlate with deletions on the derivative chromosome 9 or survival in chronic myeloid leukemia. Blood (2001) 0.83
Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia. J Clin Oncol (2003) 17.67
Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet. Blood (2009) 15.95
International consensus report on the investigation and management of primary immune thrombocytopenia. Blood (2009) 7.72
New comprehensive cytogenetic scoring system for primary myelodysplastic syndromes (MDS) and oligoblastic acute myeloid leukemia after MDS derived from an international database merge. J Clin Oncol (2012) 3.88
Efficacy of romiplostim in patients with chronic immune thrombocytopenic purpura: a double-blind randomised controlled trial. Lancet (2008) 3.74
Identification of novel cytogenetic markers with prognostic significance in a series of 968 patients with primary myelodysplastic syndromes. Haematologica (2005) 3.24
Tumor lysis syndrome in patients with acute myeloid leukemia: identification of risk factors and development of a predictive model. Haematologica (2008) 2.32
Risk-adapted treatment of acute promyelocytic leukemia with all-trans-retinoic acid and anthracycline monochemotherapy: a multicenter study by the PETHEMA group. Blood (2003) 2.27
Causes and prognostic factors of remission induction failure in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and idarubicin. Blood (2008) 2.04
Improving acute promyelocytic leukemia (APL) outcome in developing countries through networking, results of the International Consortium on APL. Blood (2013) 1.74
Morbidity and transplant-related mortality of CBV and BEAM preparative regimens for patients with lymphoid malignancies undergoing autologous stem-cell transplantation. Leuk Lymphoma (2006) 1.65
Cytogenetic risk stratification in chronic myelomonocytic leukemia. Haematologica (2010) 1.60
Influence of genetic polymorphisms on the risk of developing leukemia and on disease progression. Leuk Res (2006) 1.54
Treatment of newly diagnosed acute promyelocytic leukemia (APL): a comparison of French-Belgian-Swiss and PETHEMA results. Blood (2007) 1.53
Functional roles of Akt signaling in mouse skin tumorigenesis. Oncogene (2002) 1.49
Central nervous system involvement at first relapse in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and anthracycline monochemotherapy without intrathecal prophylaxis. Haematologica (2009) 1.44
Complexity of VEGF responses in skin carcinogenesis revealed through ex vivo assays based on a VEGF-A null mouse keratinocyte cell line. J Invest Dermatol (2008) 1.42
Additional chromosome abnormalities in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and chemotherapy. Haematologica (2009) 1.39
Platelet transfusion and thrombotic thrombocytopenic purpura. Transfusion (2002) 1.39
Fluorescence in situ hybridization analysis does not increase detection rate for trisomy 8 in chronic myelomonocytic leukemia. Leuk Lymphoma (2014) 1.39
Impact of Hospital Admission Care At a Pediatric Unit: A Qualitative Study. Pediatr Nurs (2016) 1.38
Development and validation of a prognostic scoring system for patients with chronic myelomonocytic leukemia. Blood (2013) 1.32
Incidence and prognostic value of FLT3 internal tandem duplication and D835 mutations in acute myeloid leukemia. Haematologica (2003) 1.30
A comprehensive strategy for the subtyping of patients with Fanconi anaemia: conclusions from the Spanish Fanconi Anemia Research Network. J Med Genet (2006) 1.30
Prognostic implications of Wilms' tumor gene (WT1) expression in patients with de novo acute myeloid leukemia. Haematologica (2004) 1.28
Cord-blood transplantation in patients with leukemia--a real alternative for adults. N Engl J Med (2004) 1.24
The t(4;22)(q12;q11) in atypical chronic myeloid leukaemia fuses BCR to PDGFRA. Hum Mol Genet (2002) 1.22
Clinical significance of CD56 expression in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and anthracycline-based regimens. Blood (2010) 1.20
Treatment with all-trans retinoic acid and anthracycline monochemotherapy for children with acute promyelocytic leukemia: a multicenter study by the PETHEMA Group. J Clin Oncol (2005) 1.15
DNA methylation profiles and their relationship with cytogenetic status in adult acute myeloid leukemia. PLoS One (2010) 1.15
Cord blood transplantation from unrelated donors in adults with high-risk acute myeloid leukemia. Biol Blood Marrow Transplant (2009) 1.14
Follow-up of healthy donors receiving granulocyte colony-stimulating factor for peripheral blood progenitor cell mobilization and collection. Results of the Spanish Donor Registry. Haematologica (2008) 1.12
Molecular analysis of t(15;17) genomic breakpoints in secondary acute promyelocytic leukemia arising after treatment of multiple sclerosis. Blood (2008) 1.11
Response to lenalidomide in myelodysplastic syndromes with del(5q): influence of cytogenetics and mutations. Br J Haematol (2013) 1.10
Prognostic value of FLT3 mutations in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and anthracycline monochemotherapy. Haematologica (2011) 1.09
Revision of the risk of secondary leukaemia after mitoxantrone in multiple sclerosis populations is required. Mult Scler (2009) 1.08
Profile of polymorphisms of drug-metabolising enzymes and the risk of therapy-related leukaemia. Br J Haematol (2007) 1.08
Prospective study of amphotericin B formulations in immunocompromised patients in 4 European countries. Clin Infect Dis (2006) 1.05
Viroporin activity of murine hepatitis virus E protein. FEBS Lett (2005) 1.05
Rasburicase (recombinant urate oxidase) for the management of hyperuricemia in patients with cancer: report of an international compassionate use study. Cancer (2003) 1.05
Natural variation explains most transcriptomic changes among maize plants of MON810 and comparable non-GM varieties subjected to two N-fertilization farming practices. Plant Mol Biol (2010) 1.04
Pulmonary capillary hemangiomatosis associated with primary pulmonary hypertension: report of 2 new cases and review of 35 cases from the literature. Medicine (Baltimore) (2002) 1.03
Chronic lymphocytic leukaemia with 17p deletion: a retrospective analysis of prognostic factors and therapy results. Br J Haematol (2012) 1.03
Efficacy and safety of rituximab in adult patients with idiopathic relapsing or refractory thrombotic thrombocytopenic purpura: results of a Spanish multicenter study. Transfus Apher Sci (2010) 1.03
Gene expression profiles of MON810 and comparable non-GM maize varieties cultured in the field are more similar than are those of conventional lines. Transgenic Res (2009) 1.02
The European LeukemiaNet: achievements and perspectives. Haematologica (2010) 1.02
Rapid detection of KIT mutations in core-binding factor acute myeloid leukemia using high-resolution melting analysis. J Mol Diagn (2009) 1.02
High-resolution melting analysis for rapid screening of BRCA1 and BRCA2 Spanish mutations. Breast Cancer Res Treat (2008) 1.01
Early prediction of treatment outcome in acute myeloid leukemia by measurement of WT1 transcript levels in peripheral blood samples collected after chemotherapy. Haematologica (2008) 1.01
Epigenetic regulation of the non-canonical Wnt pathway in acute myeloid leukemia. Cancer Sci (2009) 1.01
Redox activation of mitochondrial intermembrane space Cu,Zn-superoxide dismutase. Biochem J (2005) 1.00
Better prognosis for patients with del(7q) than for patients with monosomy 7 in myelodysplastic syndrome. Cancer (2011) 1.00
In vitro phenotypic correction of hematopoietic progenitors from Fanconi anemia group A knockout mice. Blood (2002) 1.00
Prognostic impact of severe thrombocytopenia in low-risk myelodysplastic syndrome. Cancer (2011) 0.99
Incidence and prognostic impact of secondary cytogenetic aberrations in a series of 145 patients with mantle cell lymphoma. Genes Chromosomes Cancer (2010) 0.98
Complex, not monosomal, karyotype is the cytogenetic marker of poorest prognosis in patients with primary myelodysplastic syndrome. J Clin Oncol (2013) 0.97
One-unit versus two-unit cord-blood transplantation. N Engl J Med (2015) 0.96
Analysis of factors associated with low peripheral blood progenitor cell collection in normal donors. Transfusion (2002) 0.96
Central nervous system involvement at first relapse in patients with acute myeloid leukemia. Haematologica (2011) 0.95
A novel NUP98/RARG gene fusion in acute myeloid leukemia resembling acute promyelocytic leukemia. Blood (2010) 0.95
Bleeding and thrombosis in acute leukemia: what does the future of therapy look like? Thromb Res (2007) 0.94
The differentiation syndrome in patients with acute promyelocytic leukemia: experience of the pethema group and review of the literature. Mediterr J Hematol Infect Dis (2011) 0.94
Impact of hematopoietic chimerism at day +14 on engraftment after unrelated donor umbilical cord blood transplantation for hematologic malignancies. Haematologica (2009) 0.94
Incidence, risk factors, and outcome of cytomegalovirus infection and disease in patients receiving prophylaxis with oral valganciclovir or intravenous ganciclovir after umbilical cord blood transplantation. Biol Blood Marrow Transplant (2009) 0.93
Intravenous busulfan and melphalan as a conditioning regimen for autologous stem cell transplantation in patients with newly diagnosed multiple myeloma: a matched comparison to a melphalan-only approach. Biol Blood Marrow Transplant (2012) 0.92
The potential effect of gender in combination with common genetic polymorphisms of drug-metabolizing enzymes on the risk of developing acute leukemia. Haematologica (2007) 0.91
Analysis of mutational status, SNP rs16754, and expression levels of Wilms tumor 1 (WT1) gene in acute promyelocytic leukemia. Ann Hematol (2012) 0.89
Early intervention during imatinib therapy in patients with newly diagnosed chronic-phase chronic myeloid leukemia: a study of the Spanish PETHEMA group. Haematologica (2010) 0.88
Fluorescence in situ hybridization improves the detection of 5q31 deletion in myelodysplastic syndromes without cytogenetic evidence of 5q-. Haematologica (2008) 0.88